-
Product Insights
NewPoly – Drugs In Development, 2024
The Poly pipeline drugs market research report outlays comprehensive information on the Poly targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Unspecified Cancer, and Solid Tumor. It also reviews key players involved in Poly targeted therapeutics development with respective active and dormant or discontinued projects. Note: * This is an “on-demand” report...
-
Product Insights
NewPoly [ADP Ribose] Polymerase 2 – Drugs In Development, 2024
The Poly [ADP Ribose] Polymerase 2 pipeline drugs market research report outlays comprehensive information on the Poly [ADP Ribose] Polymerase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Infectious Disease, and Undisclosed which include indications of Ovarian Cancer, Solid Tumor, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, and Unspecified. It also reviews key...
-
Product Insights
NewPoly [ADP Ribose] Polymerase 1 – Drugs In Development, 2024
The Poly [ADP Ribose] Polymerase 1 pipeline drugs market research report outlays comprehensive information on the Poly [ADP Ribose] Polymerase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Undisclosed, Infectious Disease, and Respiratory which include indications of Ovarian Cancer, Solid Tumor, Unspecified, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, and Lung Injury. It...
-
Product Insights
NewPoly [ADP Ribose] Polymerase 3 – Drugs In Development, 2024
The Poly [ADP Ribose] Polymerase 3 pipeline drugs market research report outlays comprehensive information on the Poly [ADP Ribose] Polymerase 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Cervical Cancer, and Solid Tumor. It also reviews key players involved in Poly [ADP Ribose] Polymerase 3 targeted therapeutics development with respective active...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Poly-ICLC in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Poly-ICLC in Prostate Cancer Drug Details: Poly-ICLC (Hiltonol) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Pediatric Diffuse Intrinsic Pontine Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Poly-ICLC in Pediatric Diffuse Intrinsic Pontine Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Poly-ICLC in Pediatric Diffuse Intrinsic Pontine Glioma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YSON-001 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YSON-001 in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YSON-001 in Metastatic Breast Cancer Drug Details: YS-ON-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YSON-001 in Metastatic Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YSON-001 in Metastatic Liver Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YSON-001 in Metastatic Liver Cancer Drug Details: YS-ON-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YSON-001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YSON-001 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YSON-001 in Solid Tumor Drug Details: YS-ON-001 is under development for...